NCT07503210

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

Efficacy and Safety of NNC0487-0111 s.c. Once Weekly in Participants With Obesity Who Have Reached Target Dose During run-in Period (AMAZE 12)

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 600 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this clinical study is to find out if NNC0487-0111 is safe and effective for treating people who have excess body weight. There are 2 study treatments in this study taken as injections under the skin once a week. Participants will either get NNC0487-0111 (the treatment being tested) or Placebo (a treatment that has no active medicine in it). Which treatment participants get is decided by chance.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	NNC0487-0111	NNC0487-0111 will be administered subcutaneously.
DRUG	Placebo (matched to NNC0487-0111)	Placebo will be administered subcutaneously.

Timeline

• Start date: 2026-04-21
• Primary completion: 2028-06-06
• Completion: 2028-07-04
• First posted: 2026-03-31
• Last updated: 2026-03-31

Locations

72 sites across 12 countries: United States, Argentina, Australia, Belgium, Bulgaria, Denmark, France, Germany, Italy, Netherlands, Spain, United Kingdom

Regulatory

• FDA-regulated drug study